Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genesis Healthcare (GEN) and Spruce Biosciences (SPRB).
Genesis Healthcare (GEN)
In a report issued on November 18, Frank Morgan from RBC Capital maintained a Hold rating on Genesis Healthcare, with a price target of $0.50. The company’s shares closed last Thursday at $0.49, close to its 52-week low of $0.40.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 15.2% and a 67.1% success rate. Morgan covers the Healthcare sector, focusing on stocks such as Fresenius Medical Care, Acadia Healthcare, and Tenet Healthcare.
Currently, the analyst consensus on Genesis Healthcare is a Hold with an average price target of $0.54, implying an 8.0% upside from current levels. In a report issued on November 11, Credit Suisse also maintained a Hold rating on the stock with a $0.57 price target.
See today’s analyst top recommended stocks >>
Spruce Biosciences (SPRB)
In a report issued on November 18, Gregory Renza from RBC Capital maintained a Buy rating on Spruce Biosciences, with a price target of $28.00. The company’s shares closed last Thursday at $26.55, close to its 52-week high of $27.31.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 27.6% and a 61.9% success rate. Renza covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, ACADIA Pharmaceuticals, and Aprea Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Spruce Biosciences with a $33.75 average price target, implying a 37.7% upside from current levels. In a report issued on November 3, Credit Suisse also initiated coverage with a Buy rating on the stock with a $28.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
